Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 426-840-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Acclimatization: October 15, 1996 - Termination: November 05, 1996
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- adopted February 24, 1987
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Version / remarks:
- July 31, 1992
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: HanIbm: WIST (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BRL, Biological Research Laboratories Ltd. Wolferstrasse 4, 4414 Fullinsdorf I Switzerland
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation (age when treated): males 8 weeks, females 10 weeks
- Weight at study initiation (body weight range when treated): males 199.8-207.0 g, females 169.8-193.3 g
- Fasting period before study: overnight fasting period prior to application
- Housing: Groups of five in Makrolon type-4 cages with standard softwood bedding ("LignocelN, Schill AG, CH-4132 Muttenz).
- Diet (e.g. ad libitum): Pelleted standard Kliba 343, Batch no. 78/96 rat maintenance diet (Kliba MOhlen AG, CH-4303 Kaiseraugst) available ad libitum (except for the overnight fasting period prior to application). Results of analyses for contaminants are included in the report.
- Water (e.g. ad libitum):Community tap water from Itingen, available ad libitum. Results of bacteriological, chemical and contaminant analyses are included in the report.
- Acclimation period:One week under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): between 40-70% (values above 70% during cleaning process possible)
- Air changes (per hr): Air-conditioned with 10-15 air changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours artificial fluorescent light/12 hours dark, music during the light period
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- bi-distilled water
- Details on oral exposure:
- VEHICLE: bi-distilled water
- Concentration in vehicle: 0.2g test item/ml vehicle
- Amount of vehicle (if gavage): 10 ml vehicle/kg bw
- Justification for choice of vehicle: not detailed
- Lot/batch no. (if required): not detailed
- Purity: not detailed
MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg body weight
DOSAGE PREPARATION (if unusual):
The test article was placed into a glass beaker on a tared Mettler PM 460 balance and the vehicle (bi-distilled water) was added. A weight by volume dilution was prepared using a glass rod and a magnetic stirrer (Janke & Kunkel,
0-79219 Staufen) as homogenizers. Homogeneity of the test article in the vehicle was maintained during treatment using the same magnetic stirrer (Janke & Kunkel, 0-79219 Staufen). The preparation was made shortly before dosing.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: limit concentration of 2000 mg/kg bw
TREATMENT
The animals received a single dose of the test article on a mg/kg body weight basis by oral gavage following fasting for approximately 18 hours, but with free access to water. Food was provided again approximately 3 hours after dosing. - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 15 days
- Frequency of observations and weighing:
MORTALITY/VIABILITY: four times during test day 1 and once daily for surviving animals during days 2-15.
CLINICAL SIGNS: each animal was examined for changes in appearance and behaviour four times during day l, and once daily for surviving animals during days 2-15. All abnormalities were recorded.
BODY WEIGHTS: on test day 1 (pre-administration), 8 and 15 for surviving animals.
- Necropsy of survivors performed: yes
Necropsies were performed by experienced prosectors. At the end of the observation period all animals were sacrificed by intraperitoneal injection of NARCOREN (Rhone Merieux GmbH, D-88471 Laupheim) at a dose of at least 2.0 ml/kg body weight (equivalent to at least 320 mg sodium pentobarbitone/kg body weight). The animals were examined macroscopically. Thereafter, they were discarded.
- Other examinations performed: - - Statistics:
- The LOGIT-Model could not be used as no deaths occured.
- Preliminary study:
- Not performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occurred during the study.
- Clinical signs:
- No clinical signs of toxicity were observed during the study period.
- Body weight:
- The body weight of the animals was within the range of physiological variability known for rats of this strain and age.
- Gross pathology:
- No macroscopic findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The mean lethal dose of SCARLET RN 1165 after single oral administration to rats of both sexes, observed over a period of 14 days, could not be estimated because LD50: greater than 2000 mg/kg.
- Executive summary:
A group of five male and 5 female Han!bm:WIST (SPF) rats was treated with SCARLET RN 1165 at 2000 mg/kg by oral gavage. The test article was suspended in vehicle (bi-distilled water) at a concentration of 0.2 g/ml and administered at a volume of 10 ml/kg. Four times during day 1 and once daily during days 2-15 the animals were examined for clinical signs. Mortality/viability were recorded together with clinical signs at the same time intervals. Body weights were recorded on day 1 before administration and on days 8 and 15. All animals were necropsied and examined macroscopically.
No deaths occurred during the study.
No clinical signs of toxicity were observed during the observation period.
The body weight of the animals was within the range of physiological variability known for rats of this strain and age.
No macroscopic findings were observed at necropsy.
CONCLUSION
The mean lethal dose of SCARLET RN 1165 after single oral administration to rats of both sexes, observed over a period of 14 days, could not be estimated, because LD50: greater than 2000 mg/kg
Reference
Evolution of body weight (in grams):
Sex/dose |
Animal No. |
Day 1 (= day of treatment) |
Day 8 |
Day 15 |
Male / 2000 mg/kg |
1 |
204.6 |
272.1 |
305.3 |
2 |
207.0 |
265.1 |
278.6 |
|
3 |
201.9 |
253.3 |
277.0 |
|
4 |
199.8 |
260.7 |
286.1 |
|
5 |
200.2 |
253.9 |
286.1 |
|
Female/ 2000 mg/kg |
6 |
193.1 |
221.1 |
232.2 |
7 |
189.5 |
209.4 |
215.4 |
|
8 |
169.8 |
192.5 |
209.2 |
|
9 |
186.6 |
215.4 |
222.8 |
|
10 |
193.3 |
232.9 |
238.7 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Klimisch code 1
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Acclimatization: October 15, 1996 - Report: November 26, 1996
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- February 24, 1987
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- July 31, 1992
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: HanIbm: WIST (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BRL, Biological Research Laboratories Ltd. Wolferstrasse 4, 4414 FOllinsdorf I Switzerland
- Females (if applicable) nulliparous and non-pregnant: no
- Age when treated: 8 weeks (males), 11 weeks (females)
- Weight when treated: males 231.0-243.6 g, females 203.3-222.9 g
- Housing: During acclimatization in groups of five in Makrolon type-4 cages with standard softwood bedding ("Lignocel", Schill AG, CH-4132 Muttenz). During treatment and observation individually in Makrolon type-3 cages with standard softwood bedding.
- Diet (e.g. ad libitum): Pelleted standard Kliba 343, Batch no. 78/96 rat maintenance diet (Kliba Muhlen AG, CH-4303 Kaiseraugst) available ad libitum.
- Water (e.g. ad libitum): Community tap water from Itingen, available ad libitum.
- Acclimation period:One week under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 40-70% (values above 70% during cleaning process possible)
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12 (music was played during the daytime light period)
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Remarks:
- bio-distilled water
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back
- % coverage: 10%
- Type of wrap if used: the dressing was wrapped around the abdomen and fixed with an elastic adhesive bandage
REMOVAL OF TEST SUBSTANCE
- Washing (if done): twenty-four hours after the application the dressing was removed and the skin was washed with lukewarm tap water and dried with disposable paper towels.
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg body weight
- Concentration (if solution): 0.5 g/ mL vehicle
- Constant volume or concentration used: yes
VEHICLE: bi-distilled water
- Amount(s) applied (volume or weight with unit): 4 mL (vehicle + test item)/kg
- Concentration (if solution): 0.5 g/ mL vehicle - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality/viability: Four times during test day 1 and once daily for surviving animals during days 2-15.
- Necropsy of survivors performed: yes
Necropsies were performed by experienced prosectors. At the end of the observation period all animals were sacrificed by intraperitoneal injection of NARCDREN (Rhone Merieux GmbH, D-88471 Laupheim) at a dose of at least 2.0 ml/kg body weight (equivalent to at least 320 mg sodium pentobarbitone/kg body weight). The animals were examined macroscopically and all abnormalities recorded. Thereafter, they were discarded.
- Other examinations performed: clinical signs, body weight, organ weights, histopathology, ...
Body weights: On test days 1 (pre-administration), 8 and 15 for surviving animals.
Clinical signs: Each animal was examined for changes in behaviour and appearance (with special emphasis on the application area, except for the time when the semi-occlusive dressing was in place) four times during day 1, and once daily during days 2-15. All abnormalities were recorded. - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths occurred during the study.
- Clinical signs:
- No clinical signs of toxicity were observed.
Red discoloration of the skin at the application site was evident in all animals after the removal of the dressing on test day 2 and persisted until study termination. Residual test article was noted in three males and one female. - Body weight:
- The body weight of the animals was within the range of physiological variability known for rats of this strain and age. For results, please refer to the table in "Any other information on results incl. tables" hereafter.
- Gross pathology:
- No macroscopic organ findings were observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The dermal LDso (rat) of SCARLET RN 1165 is > 2000 mg/kg bw in test performed according to OECD TG 402 and following GLP.
- Executive summary:
A group of five male and 5 female Hanibm:WIST (SPF) rats was treated with SCARLET RN 1165 at 2000 mg/kg by dermal application. The test article was suspended in vehicle (bi-distilled water) at a concentration of 0.5 g/ml and administered at a volume of 4 ml/kg. Four times during day 1 and once daily during days 2-15 the animals were examined for clinical signs.
Mortality/viability were recorded together with clinical signs at the same time intervals. Body weights were recorded on day 1 before administration and on days 8 and 15. All animals were necropsied and examined macroscopically.
No deaths occurred during the study period.
Red skin (back) and residual test article (back) were observed on the test sites.
The body weight of the animals was within the range of physiological variability known for rats of this strain and age.
No macroscopic organ findings were observed at necropsy.
The mean lethal dose of SCARLET RN 1165 after single dermal administration to rats of both sexes, observed over a period of 14 days, could not be estimated, because : LD50 greater than 2000 mg/kg
Reference
Evolution of body weight (in grams) :
Sex/dose |
Animal No. |
Day 1 (= day of treatment) |
Day 8 |
Day 15 |
Male / 2000 mg/kg |
1 |
231.0 |
250.3 |
270.4 |
2 |
240.2 |
267.1 |
294.8 |
|
3 |
243.6 |
269.6 |
296.9 |
|
4 |
239.1 |
262.0 |
280.6 |
|
5 |
232.4 |
261.5 |
293.5 |
|
Female / 2000 mg/kg |
6 |
208.9 |
228.6 |
250.6 |
7 |
203.3 |
214.6 |
222.1 |
|
8 |
222.9 |
224.9 |
232.6 |
|
9 |
208.6 |
221.0 |
237.0 |
|
10 |
209.9 |
221.9 |
235.4 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Klimisch code 1
Additional information
Justification for classification or non-classification
For each route of exposure, the LD50/LC50 is > threshold dose leading to classification according to CLP criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.